EGAGenomicsForensic or Paleo-genomicshttps://ega-archive.org/studies/EGAS00001007090EGAEGA study EGAS00001007090CyclomicsSeq_PREDICT_R10CyclomicsSeq_Healthy_R9CyclomicsSeq_Synthetic_R9CyclomicsSeq_IMCISION_FlongleCyclomicsSeq_Healthy_FlongleCyclomicsSeq_Synthetic_FlongleCyclomicsSeq_PREDICT_R9CyclomicsSeq_IMCISION_R9EGArestricted0998/12, Head Neoplasms, Consensus., single-organism developmental process, PNT-P1, ETS2, Neoplasms, Ets2, DmelCG17077, postnatal development, Cancer of the Head, Neck Neoplasms, EY3-1, Head Cancer, growth and development, Pnt, Development, Head, DMPOINT1A, pntegfr, 0608/07, png, Head and Neck Cancer, Head and Neck Neoplasm, responsivity, UADT Neoplasm, Relapses, D-ets-2, 3520, UADT, Upper Aerodigestive Tract Neoplasms, Pnt-P1, treatment, reactivity, pointed-RC, Recrudescences, Recurrences, Cancer of Head and Neck, Head Cancers, Neck, EK3-2, l(3)07825, disease management, Therapies, Cancer of Neck, CG17077, tumour of head and neck, Consensus Development, head/neck neoplasm, l(3)j1B7, Cancer, Therapy, Neck Cancer, Relapse, Ets, head and neck neoplasm, D-Ets-2, ets94F, 0123/09, Cancer of the Neck, Nanopore, development, Head Neoplasm, Recrudescence, Neoplasm, Upper Aerodigestive Tract, Neck Cancers, pnt-P1, pnt-P2, l(3)s118306, pntP2, Pointed-P1, Cancer of the Head and Neck, Upper Aerodigestive Tract Neoplasm, Ets94F, postnatal growth, Cancers, UADT Neoplasms, Treatments, ptd, head and neck tumours, PntP2, Neck Neoplasm, head and neck tumors, Ets58AB, carcinoma of the neck, Head and Neck, Therapeutic, PntP1, E(E2F)3D, Treatment, PNTP2, response, growth, PNTP1, POINT, Cancer of Head, CG8705Tumor DNA, Head Neoplasms, Biological Markers, Viral Marker, Surrogate Endpoints, Laboratory, Biochemical, Cancer of the Head, Endpoint, Head And Neck, Circulating, neutral molecular compounds, Serum, Tumor, Squamous Cell Carcinoma, Circulating Tumor, Tp53, Long Term, squamous cell cancer, dmTAF[[II]]230, Head, Laboratory Markers, Techniques, Biological, Method, bbl, Cell-Free, UADT Neoplasm, Effect, molecule, UADT, Upper Aerodigestive Tract Neoplasms, squamous carcinoma, epidermoid cell cancer, molecula, squamous cell epithelioma, thymus nucleic acid, molecules, malignant squamous cell neoplasm, Biopsies, TFIID TAF250, BCC7, cel, squamous cell carcinoma (morphologic abnormality), squamous cell, Head And Neck Squamous Cell Carcinomas, Molekuel, procedures, Cancer of Head and Neck, Oral Squamous Cell Carcinomas, Neck, free, allergic reaction, Immune, Markers, Methodological Studies, Viral Markers, Malignancies, Double-Stranded DNA, deoxyribonucleic acids, DNAn, Squamous Cell of Head and Neck, Long-Term Effects, Tumors, Carcinoma, dTAF[[II]]230, Viral, Surrogate Endpoint, head and neck neoplasm, Longterm Effect, TAF200, Planocellular, Biochemical Markers, Cell Free Tumor DNA, Double-Stranded, Squamous, TAFII-250, Procedure, TAF250/230, Biologic Marker, Nanopore, malignant epidermoid cell tumor, (Deoxyribonucleotide)n+m, TAFII250, Benign, Marker, epidermoid carcinoma, Cell-Free Tumor DNA, Oral Squamous Cell Carcinoma, Upper Aerodigestive Tract, bfy, Neck Cancers, desoxyribose nucleic acid, Carcinomas, Squamous Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Nanopore Sequencings, Squamous Cell, Planocellular Carcinoma, End Points, Epidermoid, Cancer of the Head and Neck, Upper Aerodigestive Tract Neoplasm, Laryngeal Squamous Cell Carcinoma, Benign Neoplasms, malignant squamous cell tumour, carcinoma of the head and neck, Immunologic, Methodological, Laboratory Marker, CG17603, TAF[[II]], Methodological Study, UADT Neoplasms, Malignant Neoplasms, Neck Neoplasm, Taf250, Patient, Head and Neck, Biochemical Marker, SR3-5, squamous cell carcinoma NOS (morphologic abnormality), ds DNA, P53, p44, bhy, DNA, other neoplasm, TAF230, d230, DNS, Procedures, (Deoxyribonucleotide)n, Clinical Markers, Effects, Clinical Marker, Neoplasms, p53, Benign Neoplasm, Neck Neoplasms, dTAFII250, Head Cancer, malignant squamous cell tumor, Malignant, EfW1, LFS1, Deoxyribonucleic acids, Surrogate End Points, Planocellular Carcinomas, Surrogate Markers, method, Epidermoid Carcinomas, Head and Neck Cancer, Deoxyribonucleic Acid, Head and Neck Neoplasm, dmTAF1, sensitive, Taf230, method used in an experiment, Studies, HNSCC, sensitivity, Technique, TAF250, Biomarker, malignant epidermoid cell tumour, Taf200, dTAF[[II]]250, malignant epidermoid cell neoplasm, Clinical, Malignancy, Longterm, cell, Biological Marker, Double Stranded, Taf1p, Deoxyribonucleic acid, Long-Term, Head Cancers, Sequencing, Neoplasias, Study, Squamous Cell Carcinoma of the Larynx., dTAF250, Cell-Free Tumor, Immunologic Markers, Trp53, Clients, Cancer of Neck, liquid, Long-Term Effect, tumour of head and neck, (Deoxyribonucleotide)m, head/neck neoplasm, carcinoma, TRP53, TAF, Immunologic Marker, Biologic, Cancer, Neck Cancer, TAF[[II]]250, Squamous Cell Carcinoma of the Mouth, Malignant Neoplasm, whole blood, Squamous Cell Carcinoma of the Nasal Cavity, malignant, DNAn+1, Serum Markers, Squamous Cell Carcinoma of the Head and Neck, End Point, l(3)84Ab, BG:DS00004.13, Cancer of the Neck, Client, Cell, Immune Marker, Xp53, dTAF230, Hypopharyngeal Squamous Cell Carcinoma, Head Neoplasm, Surrogate End Point, p230, Long Term Effects, Neoplasm, TAF[[II]]250/230, TFIID, Squamous Cell Carcinomas, techniques, ds-DNA, Biologic Markers, Taf[[II]]250, Serum Marker, TAF[[II]]230, Surrogate, Endpoints, Oral Tongue Squamous Cell Carcinoma, TAF[II]250, Cancers, squamous cell Epithelioma, Surrogate Marker, Longterm Effects, plan specification, head and neck tumours, head and neck tumors, carcinoma of the neck, DmelCG17603, Oral Cavity Squamous Cell Carcinoma, Squamous Cell Carcinoma of Larynx, Desoxyribonukleinsaeure, Squamous Carcinomas, SCC, Head and Neck Squamous Cell Carcinoma, Epidermoid Carcinoma, Neoplasia, methodology, Cancer of Head, Immune Markers, TAF1, squamous cell carcinomafalsePoint-of-care monitoring of head and neck cancer treatment response and recurrence development using nanopore-based ctDNA consensus sequencingLevels of circulating tumor DNA (ctDNA) in liquid biopsies may serve as a sensitive biomarker for real-time, minimally-invasive tumor diagnostics and monitoring. However, detecting ctDNA is challenging, as much fewer than 5% of the cell-free DNA in the blood typically originates from the tumor. To detect lowly abundant molecules, extremely sensitive sequencing methods are required. We developed a new technique, CyclomicsSeq, which is based on Oxford Nanopore sequencing of concatenated copies of a single DNA molecule, and applied this to amplicon(s) of TP53 in patients with advanced head and neck cancer squamous cell carcinoma (HNSCC) and healthy controls.2023-03-23 10:02:36EGAS000010070909606EGAD00001010153EGAD00001010154EGAD00001010151EGAD00001010148EGAD00001010149EGAD00001010150EGAD00001010155EGAD00001010152EGAC00001000432